Most of the cancer cells are androgen dependent, and when androgen levels fall, it can cause prostate epithelial shrinkage in adults, and it can cause the same changes in prostate cancer cells. It is on this basis that endocrine therapies are developed, with anti-androgen therapy at their core. Because of the insidious nature of prostate cancer symptoms, most prostate cancers are found to be in the middle to late stages, so androgen suppression endocrine therapy becomes the basis of treatment for middle to late stage prostate cancer. At present, endocrine therapy is an important treatment tool for sitting prostate cancer and is widely used in clinical practice. Its treatment methods mainly include orchiectomy, application of estrogen, androgen antagonist antagonist therapy, luteinizing hormone-releasing hormone therapy and combined endocrine therapy. Androgens can make prostate cancer cells proliferate actively, so it can be treated by bilateral orchiectomy. Osteotomy can reduce serum testosterone from 500 nanograms per deciliter (ng/dl) to 50 nanograms per deciliter (ng/dl), thus effectively stopping the metabolism of most androgen-dependent prostate cancers and causing the cancer to regress. Paroxysmal fever, sweating, and impotence may occur after orchiectomy. The advantage of orchiectomy is that it removes the main source of androgens from the body, does not increase another hormone in the body, does not have side effects such as anemia and cardiovascular lesions that occur after taking estrogen, i.e., occasional liver failure, and does not have the problem of patients being unable to adhere to long-term medication, and can The treatment can be completed at once. 2. Estrogen Both natural and synthetic estrogens can lower testosterone levels through the pituitary gonadal axis and inhibit the release of luteinizing hormone (LH) from the pituitary gland. It can also increase sex steroid binding globulin, reduce testosterone synthesis in the testes, increase pituitary prolactin secretion, reduce DNA synthesis in the prostate cells, and bring testosterone to a desiccated level. This affects the metabolism of the prostate cells and causes the gland to atrophy. The most commonly used drug is hexestrol, the main side effects are breast development, impotence, nausea, vomiting, etc. Large doses can cause cardiovascular complications. 3, anti-androgen drugs The main effect is to prevent androgens from acting on target cells and inhibit DNA synthesis in the nucleus of prostate cells. This includes both steroids and non-steroids. Flutamide is a non-steroidal anti-androgen drug. Flutamide has no hormonal effects other than anti-androgenic effects, and therefore has fewer side effects. Feminization of male breast or breast tenderness, breast overflow, etc. are common. Flutamide can be produced in China and is covered by medical insurance. 4.Luteinizing hormone releasing hormone analogue (LHRH-A) can increase the level of testosterone and LH at the beginning of use, but the level of LH and testosterone will start to decrease after one week of application, and the level of desogestrel can be reached in 3-4 weeks. LHRH-A treatment has the advantages of less side effects and no cardiovascular complications compared with oral estrogen treatment. Buserelin is commonly used, and it can achieve the level of drug de-testosterone in one month. Adrenocorticotropic hormone therapy Because adrenocorticotropic hormone can inhibit the production of androgens by the adrenal glands, it is used to treat prostate cancer and can improve the general condition, so it is used as palliative therapy. At present, it is less used. Endocrine therapy mainly involves removing androgens of testicular origin by drugs or surgery and blocking the effect of other sources of androgens on cancer cells with anti-androgen drugs. The main program is bilateral orchiectomy + flutamide or the combination of LHRH-A + flutamide. Early application of endocrine combination therapy may prolong the survival of patients. Clinical data have confirmed the remarkable efficacy of this therapy. In some typical medical records, the recent results of this endocrine combination therapy are quite outstanding. Considering the risks, side effects, costs and impact on quality of life, endocrine combination therapy is a better treatment option for most elderly prostate cancer patients.